<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512849</url>
  </required_header>
  <id_info>
    <org_study_id>TA-7284-07</org_study_id>
    <nct_id>NCT01512849</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</brief_title>
  <official_title>An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with
      type 2 diabetes mellitus who have moderate renal impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 2-way crossover study to evaluate the PK/PD and safety of
      TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment relative
      to patients with type 2 diabetes mellitus who have normal renal function. The patients will
      receive both TA-7284-Low and TA-7284-High orally alone in either Period 1 or 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Renal Function on Maximum Plasma Concentration of TA-7284</measure>
    <time_frame>For 72 hours after each administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284</measure>
    <time_frame>For 72 hours after each administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Renal Function on Urinary Glucose Excretion of TA-7284</measure>
    <time_frame>For 24 hours after each administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284</measure>
    <time_frame>For 24 hours after each administration</time_frame>
    <description>The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC - urinary glucose excretion) on the preceding day and on the day of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Upto approximately 14 days after last administration</time_frame>
    <description>Incidence and severity of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG)</measure>
    <time_frame>For 72 hours after each administration</time_frame>
    <description>Change from baseline in ECG parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>For 72 hours after each administration</time_frame>
    <description>Change from baseline in Vital signs (BP, PR and BT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>For 72 hours after each administration</time_frame>
    <description>Change from baseline in Clinical laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TA-7284 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-7284 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-7284 Low</intervention_name>
    <description>Low</description>
    <arm_group_label>TA-7284 Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-7284 High</intervention_name>
    <description>High</description>
    <arm_group_label>TA-7284 High</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus in stable condition who have normal renal
             function or moderate renal impairment

          -  Body mass index of ≥18.5 kg/m2 and ≤39.9 kg/m2 at screening

          -  HbA1c of ≥6.5% and ≤10.5% at screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder,
             secondary diabetes mellitus

          -  Past or current history of severe diabetic complications

          -  Patients requiring insulin therapy

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuya Inagaki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuoki Kondo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>May 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TA-7284</keyword>
  <keyword>JNJ-28431754</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>Renal Impairment</keyword>
  <keyword>Sodium Glucose Co-transporter2 (SGLT2) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Moderate Renal Impairment Low Dose First</title>
          <description>TA-7284 Low dose in Period 1, then crossover to TA-7284 High dose in Period 2</description>
        </group>
        <group group_id="P2">
          <title>Moderate Renal Impairment High Dose First</title>
          <description>TA-7284 High dose in Period 1, then crossover to TA-7284 Low dose in Period 2</description>
        </group>
        <group group_id="P3">
          <title>Normal Renal Function Low Dose First</title>
          <description>TA-7284 Low dose in Period 1, then crossover to TA-7284 High dose in Period 2</description>
        </group>
        <group group_id="P4">
          <title>Normal Renal Function High Dose First</title>
          <description>TA-7284 High dose in Period 1, then crossover to TA-7284 Low dose in Period 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Crossover Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Population for Moderate Renal Impairment</title>
        </group>
        <group group_id="B2">
          <title>Entire Population for Normal Renal Function</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="10.2" lower_limit="40" upper_limit="78"/>
                    <measurement group_id="B2" value="57.8" spread="9.7" lower_limit="48" upper_limit="76"/>
                    <measurement group_id="B3" value="60.8" lower_limit="40" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Renal Function on Maximum Plasma Concentration of TA-7284</title>
        <time_frame>For 72 hours after each administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Renal Impairment Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
          <group group_id="O3">
            <title>Normal Renal Function Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O4">
            <title>Normal Renal Function High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Renal Function on Maximum Plasma Concentration of TA-7284</title>
          <units>ng / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1197.1264" spread="310.5625"/>
                    <measurement group_id="O2" value="2333.3617" spread="414.8957"/>
                    <measurement group_id="O3" value="1213.6571" spread="337.8705"/>
                    <measurement group_id="O4" value="2415.6109" spread="739.8783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Incidence and severity of AEs</description>
        <time_frame>Upto approximately 14 days after last administration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead Electrocardiogram (ECG)</title>
        <description>Change from baseline in ECG parameters</description>
        <time_frame>For 72 hours after each administration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <description>Change from baseline in Vital signs (BP, PR and BT)</description>
        <time_frame>For 72 hours after each administration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Tests</title>
        <description>Change from baseline in Clinical laboratory tests</description>
        <time_frame>For 72 hours after each administration</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284</title>
        <time_frame>For 72 hours after each administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Renal Impairment Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
          <group group_id="O3">
            <title>Normal Renal Function Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O4">
            <title>Normal Renal Function High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284</title>
          <units>ng･h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8766" spread="2551"/>
                    <measurement group_id="O2" value="17835" spread="4434"/>
                    <measurement group_id="O3" value="6929" spread="1734"/>
                    <measurement group_id="O4" value="14815" spread="4162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Renal Function on Urinary Glucose Excretion of TA-7284</title>
        <time_frame>For 24 hours after each administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Renal Impairment Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
          <group group_id="O3">
            <title>Normal Renal Function Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O4">
            <title>Normal Renal Function High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Renal Function on Urinary Glucose Excretion of TA-7284</title>
          <units>g</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.017" lower_limit="49.362" upper_limit="72.671"/>
                    <measurement group_id="O2" value="70.904" lower_limit="59.184" upper_limit="82.624"/>
                    <measurement group_id="O3" value="86.592" lower_limit="75.612" upper_limit="97.572"/>
                    <measurement group_id="O4" value="103.052" lower_limit="88.952" upper_limit="117.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284</title>
        <description>The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC – urinary glucose excretion) on the preceding day and on the day of administration.</description>
        <time_frame>For 24 hours after each administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Renal Impairment Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
          <group group_id="O3">
            <title>Normal Renal Function Low</title>
            <description>TA-7284-Low was administered in a single dose.</description>
          </group>
          <group group_id="O4">
            <title>Normal Renal Function High</title>
            <description>TA-7284-High was administered in a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284</title>
          <description>The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC – urinary glucose excretion) on the preceding day and on the day of administration.</description>
          <units>percent of RGR at baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="52.4" upper_limit="69.2"/>
                    <measurement group_id="O2" value="66.5" lower_limit="59.5" upper_limit="73.5"/>
                    <measurement group_id="O3" value="47.8" lower_limit="42.2" upper_limit="53.4"/>
                    <measurement group_id="O4" value="52.7" lower_limit="45.4" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 14 days after last administration</time_frame>
      <desc>Serious adverse events and the other adverse events were summarized in terms of renal function and dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moderate Renal Impairment Low</title>
          <description>TA-7284-Low was administered in a single dose.</description>
        </group>
        <group group_id="E2">
          <title>Moderate Renal Impairment High</title>
          <description>TA-7284-High was administered in a single dose.</description>
        </group>
        <group group_id="E3">
          <title>Normal Renal Function Low</title>
          <description>TA-7284-Low was administered in a single dose.</description>
        </group>
        <group group_id="E4">
          <title>Normal Renal Function High</title>
          <description>TA-7284-High was administered in a single dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatin phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

